Koshidacin B, a cyclic tetrapeptide, exhibits potent antiplasmodial activity, evidenced by its ability to inhibit Plasmodium falciparum strains FCR3 and K1 with IC50 values of 0.89 μM and 0.83 μM, respectively. It has been shown to effectively suppress malaria parasites in vivo and has potential applications in parasitic infection research [1].

Koshidacin B exhibits antiplasmodial properties, efficacious against both chloroquine-sensitive P. falciparum FCR3 and chloroquine-resistant P. falciparum K1 strains, presenting IC50 values of 0.89 μM and 0.83 μM after a 72-hour exposure, respectively [1]. Additionally, a 7-day exposure to Koshidacin B reveals cytotoxic effects on human MRC-5 cells with an IC50 of 14.7 μM [1].

Koshidacin B, administered intraperitoneally at a dosage of 30 mg/kg once daily over a four-day period, exhibits in vivo antiplasmodial activity [1].